Broadview Ventures

Broadview Ventures, founded in 2008 and headquartered in Boston, Massachusetts, is a venture capital firm focused on investing in early-stage life sciences companies. The firm specializes in cardiovascular and neurovascular diseases, aiming to bridge the translational gap between scientific research and clinical application. Broadview Ventures has a robust portfolio that includes companies such as DecImmune Therapeutics, which develops therapies to mitigate injury post-myocardial infarction, and FineHeart, a French medical device company creating innovative cardiac support technologies. Other notable investments include GI Windows, developing non-surgical approaches for treating chronic diseases, and Adient Medical, focusing on absorbable medical devices. The firm has made 79 investments and achieved several successful exits, including Cardialen, VentriNova, and Renovacor. Broadview's investment strategy leverages their extensive industry expertise and network to support companies from seed through later stages of development. Broadview Ventures is led by a team of experienced professionals dedicated to advancing healthcare through innovative solutions. Their strategic focus and targeted investments aim to address unmet medical needs, ultimately improving patient outcomes and advancing the field of cardiovascular and neurovascular health.